Literature DB >> 19796247

Disease models from pluripotent stem cells.

Claudia Lengerke1, George Q Daley.   

Abstract

Murine models of congenital and acquired diseases are invaluable yet often do not faithfully mirror human pathophysiology. Embryonic stem (ES) cells differentiated in vitro recapitulate aspects of early embryogenesis and differentiate into multiple somatic tissues, thereby serving as a powerful platform for developmental studies in the human. Analysis of genetically modified ES cells (by lentiviral gene transduction or derivation from embryos carrying genetic diseases, for example) offers the unprecedented opportunity to study in detail disease initiation and progression during embryonic development. ES cells and induced pluripotent stem (iPS) cells obtained by somatic cell reprogramming from patients affected by various disorders promise unique insights into the gradual pathogenesis of disease, moreover enabling development of customized cellular therapies by in vitro gene correction in autologous cells.

Entities:  

Mesh:

Year:  2009        PMID: 19796247     DOI: 10.1111/j.1749-6632.2009.04962.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  11 in total

1.  Efficient and simultaneous generation of hematopoietic and vascular progenitors from human induced pluripotent stem cells.

Authors:  Tea Soon Park; Ludovic Zimmerlin; Elias T Zambidis
Journal:  Cytometry A       Date:  2012-06-26       Impact factor: 4.355

2.  SMAD2/3, versatile molecular tools for cellular engineering.

Authors:  José Bragança
Journal:  Stem Cell Investig       Date:  2018-07-31

Review 3.  Stem cells for retinal replacement therapy.

Authors:  Jeffrey H Stern; Sally Temple
Journal:  Neurotherapeutics       Date:  2011-10       Impact factor: 7.620

Review 4.  miRNA in pluripotent stem cells.

Authors:  Uma Lakshmipathy; Jonathan Davila; Ronald P Hart
Journal:  Regen Med       Date:  2010-07       Impact factor: 3.806

5.  Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells.

Authors:  Achia Urbach; Ori Bar-Nur; George Q Daley; Nissim Benvenisty
Journal:  Cell Stem Cell       Date:  2010-05-07       Impact factor: 24.633

6.  Production of embryonic and fetal-like red blood cells from human induced pluripotent stem cells.

Authors:  Chan-Jung Chang; Koyel Mitra; Mariko Koya; Michelle Velho; Romain Desprat; Jack Lenz; Eric E Bouhassira
Journal:  PLoS One       Date:  2011-10-13       Impact factor: 3.240

Review 7.  Human heart disease: lessons from human pluripotent stem cell-derived cardiomyocytes.

Authors:  E Giacomelli; C L Mummery; M Bellin
Journal:  Cell Mol Life Sci       Date:  2017-06-01       Impact factor: 9.261

Review 8.  Induced pluripotent stem cells, a giant leap for mankind therapeutic applications.

Authors:  José Bragança; João André Lopes; Leonardo Mendes-Silva; João Miguel Almeida Santos
Journal:  World J Stem Cells       Date:  2019-07-26       Impact factor: 5.326

Review 9.  Induced pluripotent stem cell technology for disease modeling and drug screening with emphasis on lysosomal storage diseases.

Authors:  Hsiang-Po Huang; Ching-Yu Chuang; Hung-Chih Kuo
Journal:  Stem Cell Res Ther       Date:  2012-08-28       Impact factor: 6.832

10.  Induced pluripotent stem (iPS) cells offer a powerful new tool for the life sciences.

Authors:  Y Nakamura
Journal:  J Stem Cells Regen Med       Date:  2010-04-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.